Clinical trials: Cholesterol, Elevated
Hyperlipidemias
Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia
Identified the efficacy of Antroquinonol (Hocena 50mg) in triglyceride, lipid-lowering and fatty liver.
- Trial name
- NCT02719028
- Testing
- Antroquinonol
- Where
- 6 sites in Taiwan
- Volunteers
- 120 people
- Sponsor
- Golden Biotechnology Corporation
Hypercholesterolemia
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
Study of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia
- Trial name
- V-DIFFERENCE (NCT05192941)
- Testing
- Inclisiran Sodium
- Where
- 136 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 1,770 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia
A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients
This was a single-center, retrospective, observational study (non-interventional study with secondary use of data) among patients in a real-world setting. This study used the medical record data from patients in Yiling.
- Trial name
- NCT06595069
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Novartis
Hypercholesterolemia, Dyslipidemia
Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia
The purpose of this study is to determine the non-inferiority between two different FDC (fixed-dose combination), measuring LDL-Cholesterol levels, in high risk patients with primary hypercholesterolemia or mixed dyslipidemia.
- Trial name
- LANCE (NCT01420549)
- Testing
- Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation., Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
- Where
- 7 sites in Brazil
- Volunteers
- 129 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Hypercholesterolemia, Familial, Dyslipidemias
Comparison of the Plasma Lipoprotein Apheresis Systems DIAMED and MONET vs. the Whole Blood Apheresis System DALI
The clinical Investigation will be performed to compare the safety and effectiveness of the CE certified and established lipoprotein apheresis systems MONET vs. DALI and DIAMED vs.
- Conditions
- Hypercholesterolemia, Familial, Dyslipidemias, Cardiovascular Diseases
- Trial name
- DIAMOND-2018 (NCT03795038)
- Testing
- Lipoprotein Apheresis MONET and DALI, Lipoprotein Apheresis DIAMED and DALI
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Hypercholesterolemia
A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects
This is a 2-part, Phase 1, placebo-controlled, double-blind, randomized, single and multiple ascending dose study. CAT-2054 will be administered either as an uncoated capsule (CAT-2054) or a coated capsule (CAT-2054-C).
- Trial name
- NCT02374047
- Testing
- CAT-2054, CAT-2054-C, Atorvastatin
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Catabasis Pharmaceuticals
Hypercholesterolemia
Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia
The purpose of this study is to determine the efficacy of lapaquistat acetate, once daily (QD), on lowering cholesterol in subjects already taking atorvastatin.
- Trial name
- NCT00143676
- Testing
- Lapaquistat acetate and atorvastatin, Atorvastatin
- Where
- 78 sites in United States
- Volunteers
- 448 people
- Sponsor
- Takeda